Add nostrils and vaginas to the readily expanding list of human tissues doctors can now grow in laboratories and successfully implant in patients.
Two long-term studies just published in the influential medical journal The Lancet outline the success doctors have achieved in transplanting both body parts. In the first study, doctors at Wake Forest University harvested cells from the genitals of four teenage girls born with a syndrome that results in underdeveloped sexual organs, coaxed those cells into a regenerative state, grew them on a scaffold, and then transplanted the resulting tissue.
After eight years of follow up, “the organs continue to function as if they were native tissue and all recipients are sexually active, report no pain, and are satisfied with their desire/arousal, lubrication, and orgasm.”
In the second study, five people had their nostrils reconstructed with their own cartilage. That tissue was harvested from their own noses, and coaxed into expanding in volume by a factor of 40. It was then implanted. The research concludes that “the clinical reconstruction of the nasal [lobe] after resection of a non-melanoma skin cancer is safe and feasible.”
While these findings are certainly eyebrow-raising — and lend hope to those suffering with disfiguration — the more important aspect of their publication can be found in an op-ed published alongside the research.
Drs. Martin A. Birchall, and Alexander M. Seifalian write that these findings can be just as frustrating as they are promising. This research is considered disruptive medicine, and disruptions can take a very, very long time to make their way into mainstream medicine. And the high cost of developing such technology often poses roadblocks. Birchall and Seifalian write:
MRI scanners continue to improve generationally. These changes, which improve the patient’s experience and accuracy of diagnosis, are sustaining innovations: they improve an existing system that is understood by patients and that supports specialised industry, doctors, and health-care systems. By contrast, tissue engineering, and the various shades of regenerative and cellular therapies it partners, is a disruptive technology. …
Early automobile technology, although highly innovative, was the preserve of those who could afford it for many years. It was only when Henry Ford’s mass production brought automobiles to everyone’s street, in numbers yet at affordable cost, that the industry of the horse-drawn carriage passed away. These two Lancet studies show that those who practise conventional tissue reconstruction and organ transplantation, and the health-care and commercial industries which support them, should finally be taking the quirky minnows of tissue engineering quite seriously. Disruptive innovation might be nigh.
As I wrote in November, it will be some time before lab-grown organs are commonly available. Clinical trials for new procedures take decades. And “private industry is going to have to raise millions and millions of dollars not around the science, but around the practicality,” William Wagner, director of regenerative medicine at the University of Pittsburgh, told me then.
Roadblocks involving time and money are not exclusive to regenerative medicine. Take antibiotic research. Approvals of new antibiotics are currently at their lowest rate, at a time when threat of drug-resistant strains haven’t been higher. Or even sunscreen. Ingredients that European companies have been using for years, which work better than the ones currently available in the United States, are stuck in regulatory limbo.
That’s why Birchall and Seifalian provide a good reminder: Let’s turn some of these gee-whiz studies into reality.
What We're Following See More »
Newt Gringrich is actively positioning himself as a possible VP nominee for Donald Trump, according to National Review. After a New York Times piece mentioned him as a possible running mate, he said, "It is an honor to be mentioned. We need a new Contract with America to outline a 100-day plan to take back Washington from the lobbyists, bureaucrats, unions, and leftists. After helping in 1980 with Reagan and 1995 as speaker I know we have to move boldly and decisively before the election results wear off and the establishment starts fighting us. That is my focus." Meanwhile, Trump told CNN he'd be "interested in vetting" John Kasich as well.
"House Democrats are stepping up pressure on Republicans to advance legislation addressing Puerto Rico’s worsening debt crisis by issuing a report arguing that austerity cuts can’t be sustained and have made the island more vulnerable to the mosquito-borne Zika virus." Democrats on the House Natural Resources Committee released a report yesterday that argued "further sharp reductions in government spending can’t be a part of a legislative solution"—especially with a rainy season boosting the mosquito population and stressing an island health system already struggling to deal with the Zika virus.
"ISIS has the capability to stage a Paris-style attack in the U.S. using local cells to strike in multiple locations and inflict dozens of casualties, according to the Obama administration's top U.S. intelligence official." Director of National Intelligence James Clapper told CNN's Peter Bergen that such a scenario is "something we worry about a lot in the United States, that they could conjure up a raid like they did in Paris or Brussels."
"Donald J. Trump said on Wednesday that he expected to reveal his vice presidential pick sometime in July—before the Republican National Convention in Cleveland—but added that he would soon announce a committee to handle the selection process, which would include Dr. Ben Carson." He said he's inclined to name a traditional political figure, unlike himself.